Synthesis and characterization of a long-acting emtricitabine prodrug nanoformulation

Ibrahim M. Ibrahim, Aditya N. Bade, Zhiyi Lin, Dhruvkumar Soni, Melinda Wojtkiewicz, Bhagya Laxmi Dyavar Shetty, Nagsen Gautam, Joellyn M. McMillan, Yazen Alnouti, Benson J. Edagwa, Howard E. Gendelman

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: A palmitoylated prodrug of emtricitabine (FTC) was synthesized to extend the drug’s half-life, antiretroviral activities and biodistribution. Methods: A modified FTC prodrug (MFTC) was synthesized by palmitoyl chloride esterification. MFTC’s chemical structure was evaluated by nuclear magnetic resonance. The created hydrophobic prodrug nanocrystals were encased into a poloxamer surfactant and the pharmacokinetics (PK), biodistribution and antiretroviral activities of the nanoformulation (NMFTC) were assessed. The conversion of MFTC to FTC triphosphates was evaluated. Results: MFTC coated with poloxamer formed stable nanocrystals (NMFTC). NMFTC demonstrated an average particle size, polydispersity index and zeta potential of 350 nm, 0.24 and −20 mV, respectively. Drug encapsulation efficiency was 90%. NMFTC was readily taken up by human monocyte-derived macrophages yielding readily detected intracellular FTC triphosphates and an extended PK profile. Conclusion: NMFTC shows improved antiretroviral activities over native FTC. This is coordinate with its extended apparent half-life. The work represents an incremental advance in the development of a long-acting FTC formulation.

Original languageEnglish (US)
Pages (from-to)6231-6247
Number of pages17
JournalInternational journal of nanomedicine
Volume14
DOIs
StatePublished - Jan 1 2019

Fingerprint

Pharmacokinetics
Prodrugs
Nanocrystals
Macrophages
Esterification
Polydispersity
Zeta potential
Poloxamer
Encapsulation
Surface active agents
Nanoparticles
Particle size
Nuclear magnetic resonance
Half-Life
Particle Size
Surface-Active Agents
Pharmaceutical Preparations
Magnetic Resonance Spectroscopy
Emtricitabine

Keywords

  • Human immunodeficiency virus type 1
  • Long-acting antiretrovirals
  • Monocyte-derived macrophage
  • Palmitoyl chloride
  • Viral reservoirs

ASJC Scopus subject areas

  • Biophysics
  • Bioengineering
  • Biomaterials
  • Pharmaceutical Science
  • Drug Discovery
  • Organic Chemistry

Cite this

Synthesis and characterization of a long-acting emtricitabine prodrug nanoformulation. / Ibrahim, Ibrahim M.; Bade, Aditya N.; Lin, Zhiyi; Soni, Dhruvkumar; Wojtkiewicz, Melinda; Shetty, Bhagya Laxmi Dyavar; Gautam, Nagsen; McMillan, Joellyn M.; Alnouti, Yazen; Edagwa, Benson J.; Gendelman, Howard E.

In: International journal of nanomedicine, Vol. 14, 01.01.2019, p. 6231-6247.

Research output: Contribution to journalArticle

Ibrahim, Ibrahim M. ; Bade, Aditya N. ; Lin, Zhiyi ; Soni, Dhruvkumar ; Wojtkiewicz, Melinda ; Shetty, Bhagya Laxmi Dyavar ; Gautam, Nagsen ; McMillan, Joellyn M. ; Alnouti, Yazen ; Edagwa, Benson J. ; Gendelman, Howard E. / Synthesis and characterization of a long-acting emtricitabine prodrug nanoformulation. In: International journal of nanomedicine. 2019 ; Vol. 14. pp. 6231-6247.
@article{61185206f01844e6b956213420469b0a,
title = "Synthesis and characterization of a long-acting emtricitabine prodrug nanoformulation",
abstract = "Purpose: A palmitoylated prodrug of emtricitabine (FTC) was synthesized to extend the drug’s half-life, antiretroviral activities and biodistribution. Methods: A modified FTC prodrug (MFTC) was synthesized by palmitoyl chloride esterification. MFTC’s chemical structure was evaluated by nuclear magnetic resonance. The created hydrophobic prodrug nanocrystals were encased into a poloxamer surfactant and the pharmacokinetics (PK), biodistribution and antiretroviral activities of the nanoformulation (NMFTC) were assessed. The conversion of MFTC to FTC triphosphates was evaluated. Results: MFTC coated with poloxamer formed stable nanocrystals (NMFTC). NMFTC demonstrated an average particle size, polydispersity index and zeta potential of 350 nm, 0.24 and −20 mV, respectively. Drug encapsulation efficiency was 90{\%}. NMFTC was readily taken up by human monocyte-derived macrophages yielding readily detected intracellular FTC triphosphates and an extended PK profile. Conclusion: NMFTC shows improved antiretroviral activities over native FTC. This is coordinate with its extended apparent half-life. The work represents an incremental advance in the development of a long-acting FTC formulation.",
keywords = "Human immunodeficiency virus type 1, Long-acting antiretrovirals, Monocyte-derived macrophage, Palmitoyl chloride, Viral reservoirs",
author = "Ibrahim, {Ibrahim M.} and Bade, {Aditya N.} and Zhiyi Lin and Dhruvkumar Soni and Melinda Wojtkiewicz and Shetty, {Bhagya Laxmi Dyavar} and Nagsen Gautam and McMillan, {Joellyn M.} and Yazen Alnouti and Edagwa, {Benson J.} and Gendelman, {Howard E.}",
year = "2019",
month = "1",
day = "1",
doi = "10.2147/IJN.S215447",
language = "English (US)",
volume = "14",
pages = "6231--6247",
journal = "International Journal of Nanomedicine",
issn = "1176-9114",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Synthesis and characterization of a long-acting emtricitabine prodrug nanoformulation

AU - Ibrahim, Ibrahim M.

AU - Bade, Aditya N.

AU - Lin, Zhiyi

AU - Soni, Dhruvkumar

AU - Wojtkiewicz, Melinda

AU - Shetty, Bhagya Laxmi Dyavar

AU - Gautam, Nagsen

AU - McMillan, Joellyn M.

AU - Alnouti, Yazen

AU - Edagwa, Benson J.

AU - Gendelman, Howard E.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Purpose: A palmitoylated prodrug of emtricitabine (FTC) was synthesized to extend the drug’s half-life, antiretroviral activities and biodistribution. Methods: A modified FTC prodrug (MFTC) was synthesized by palmitoyl chloride esterification. MFTC’s chemical structure was evaluated by nuclear magnetic resonance. The created hydrophobic prodrug nanocrystals were encased into a poloxamer surfactant and the pharmacokinetics (PK), biodistribution and antiretroviral activities of the nanoformulation (NMFTC) were assessed. The conversion of MFTC to FTC triphosphates was evaluated. Results: MFTC coated with poloxamer formed stable nanocrystals (NMFTC). NMFTC demonstrated an average particle size, polydispersity index and zeta potential of 350 nm, 0.24 and −20 mV, respectively. Drug encapsulation efficiency was 90%. NMFTC was readily taken up by human monocyte-derived macrophages yielding readily detected intracellular FTC triphosphates and an extended PK profile. Conclusion: NMFTC shows improved antiretroviral activities over native FTC. This is coordinate with its extended apparent half-life. The work represents an incremental advance in the development of a long-acting FTC formulation.

AB - Purpose: A palmitoylated prodrug of emtricitabine (FTC) was synthesized to extend the drug’s half-life, antiretroviral activities and biodistribution. Methods: A modified FTC prodrug (MFTC) was synthesized by palmitoyl chloride esterification. MFTC’s chemical structure was evaluated by nuclear magnetic resonance. The created hydrophobic prodrug nanocrystals were encased into a poloxamer surfactant and the pharmacokinetics (PK), biodistribution and antiretroviral activities of the nanoformulation (NMFTC) were assessed. The conversion of MFTC to FTC triphosphates was evaluated. Results: MFTC coated with poloxamer formed stable nanocrystals (NMFTC). NMFTC demonstrated an average particle size, polydispersity index and zeta potential of 350 nm, 0.24 and −20 mV, respectively. Drug encapsulation efficiency was 90%. NMFTC was readily taken up by human monocyte-derived macrophages yielding readily detected intracellular FTC triphosphates and an extended PK profile. Conclusion: NMFTC shows improved antiretroviral activities over native FTC. This is coordinate with its extended apparent half-life. The work represents an incremental advance in the development of a long-acting FTC formulation.

KW - Human immunodeficiency virus type 1

KW - Long-acting antiretrovirals

KW - Monocyte-derived macrophage

KW - Palmitoyl chloride

KW - Viral reservoirs

UR - http://www.scopus.com/inward/record.url?scp=85071184831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071184831&partnerID=8YFLogxK

U2 - 10.2147/IJN.S215447

DO - 10.2147/IJN.S215447

M3 - Article

C2 - 31496683

AN - SCOPUS:85071184831

VL - 14

SP - 6231

EP - 6247

JO - International Journal of Nanomedicine

JF - International Journal of Nanomedicine

SN - 1176-9114

ER -